Scandion Oncology A/S

Headquarters: Copenhagen, Denmark

Employees: 15

CEO: Dr. Bo Rode Hansen

show_chart OMX: SCOL -2.20%

Market Cap

kr515.3 Million

SEK as of April 1, 2022

US$55.0 Million

history Market Cap History

Scandion Oncology A/S market capitalization over time

Evolution of Scandion Oncology A/S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Scandion Oncology A/S

Detailed Description

Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.

Stocks & Indices

Scandion Oncology A/S has the following listings and related stock indices.

Stock: OMX: SCOL




Fruebjergvej 3

Copenhagen, 2100


Phone: 45 38 10 20 17